Dichloroacetate as a novel pharmaceutical treatment for cancer-related fatigue in melanoma
Xinyi Zhang, Won D. Lee, Brooks P. Leitner, Wanling Zhu, Andin Fosam, Zongyu Li, Rafael Calais Gaspar, Alexandra A. Halberstam, Briana Robles, Joshua D. Rabinowitz, Rachel J. Perry
Abstract
We identify a new metabolic target for cancer-related fatigue, dichloroacetate (DCA). They demonstrate that in mice, DCA preserves physical function and protects against the detrimental effects of cancer treatment by reducing cancer-induced increases in circulating lactate. As DCA is already FDA approved for another indication, these results could be rapidly translated to clinical trials for this condition for which no pharmaceutical therapies exist beyond symptom management.
Topics & Concepts
MedicineCancerMelanomaClinical trialCancer treatmentCancer-related fatigueCancer therapyOncologyPharmacologyInternal medicineCancer researchHistone Deacetylase Inhibitors ResearchCancer, Stress, Anesthesia, and Immune ResponseExercise and Physiological Responses